FDA, CDRH Receive Slight Boosts From Senate In 2016 Funding Bill
This article was originally published in The Gray Sheet
The Senate Appropriations Committee approved $10 million more in FDA funding and $1 million more in CDRH funding in 2016 than House Appropriators did in a July 16 markup, and $2 million for a Precision Medicine Initiative next year, falling far short of the President’s $10 million request for the initiative.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.